3.17

0.00% +0.00

DiaMedica Therapeutics Inc (DMAC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

DiaMedica Therapeutics Inc stock is currently priced at $3.17, with a 24-hour trading volume of 7,101. It has seen a +0.00% increased in the last 24 hours and a +21.92% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.10 pivot point. If it approaches the $3.24 resistance level, significant changes may occur.

Previous Close:

$3.17

Open:

$3.16

24h Volume:

7,101

Market Cap:

$120.35M

Revenue:

Net Income/Loss:

$-17.97M

P/E Ratio:

-5.1129

EPS:

-0.62

Net Cash Flow:

$-17.74M

1W Performance:

+1.60%

1M Performance:

+21.92%

6M Performance:

+27.31%

1Y Performance:

+81.14%

1D Range:

$3.16

$3.20

52W Range:

$1.67

$4.75

DiaMedica Therapeutics Inc Stock (DMAC) Company Profile

Name

DiaMedica Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

763 612 6755

Address

Two Carlson Parkway, Suite 260, Minneapolis, MN

Employee

Twitter

@diamedica

Next Earnings Date

2024-05-29

Latest SEC Filings

DMAC's Discussions on Twitter

DiaMedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-21	Initiated	Oppenheimer	Outperform
Feb-17-21	Initiated	ROTH Capital	Buy
Oct-30-20	Initiated	Guggenheim	Buy
Jul-08-20	Initiated	Maxim Group	Buy
Apr-30-19	Initiated	Dougherty & Company	Buy
Mar-05-19	Initiated	Lake Street	Buy

View All

DiaMedica Therapeutics Inc Stock (DMAC) Latest News

Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year? - Yahoo New Zealand News

Yahoo New Zealand News

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Earnings call: DiaMedica Therapeutics discusses Q1 progress and challenges - Investing.com India

Investing.com India

DiaMedica Therapeutics Inc (CVE:DMA): Is Breakeven Near? - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Reviewing Pharmaxis (OTCMKTS:PXSLY) and DiaMedica Therapeutics (NASDAQ:DMAC) - Defense World

Defense World

DiaMedica Therapeutics Inc Stock (DMAC) Financials Data

DiaMedica Therapeutics Inc (DMAC) Net Income 2024

DMAC net income (TTM) was -$17.97 million for the quarter ending September 30, 2023, a -36.44% decrease year-over-year.

DiaMedica Therapeutics Inc (DMAC) Cash Flow 2024

DMAC recorded a free cash flow (TTM) of -$17.73 million for the quarter ending September 30, 2023, a -52.82% decrease year-over-year.

DiaMedica Therapeutics Inc (DMAC) Earnings per Share 2024

DMAC earnings per share (TTM) was -$0.62 for the quarter ending September 30, 2023, a -29.17% decline year-over-year.

DiaMedica Therapeutics Inc Stock (DMAC) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Von Koch Thomas	10% Owner	Jun 23 '23	Buy	3.40	1,470,588	4,999,999	4,326,435
Giuffre Randall Michael	Director	Jun 23 '23	Buy	3.91	65,000	254,150	360,355
Wambeke David J.	Chief Business Officer	Jun 23 '23	Buy	3.91	38,364	150,003	507,114
Pilnik Richard D.	Director	Jun 23 '23	Buy	3.91	38,363	149,999	248,245
Pauls Dietrich John	President and CEO	Jun 23 '23	Buy	3.91	12,787	49,997	68,591
Semba Charles Pauling	Director	Jun 23 '23	Buy	3.91	12,787	49,997	29,943
Kellen Scott	CFO and Secretary	Jun 23 '23	Buy	3.91	10,000	39,100	32,290

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.